Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11085188,GC-R,"Mean GC-R numbers were 5814+/-1574 and 6816+/-1647; mean Kd values were 3.6+/-1.5 nM and 4.2+/-0.7 nM in patient and control groups, respectively.",Glucocorticoid receptors in patients with congenital adrenal hyperplasia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11085188/),,5814,6172,DB01536,4-Androstenedione
,11085188,GC-R,"Mean GC-R numbers were 5814+/-1574 and 6816+/-1647; mean Kd values were 3.6+/-1.5 nM and 4.2+/-0.7 nM in patient and control groups, respectively.",Glucocorticoid receptors in patients with congenital adrenal hyperplasia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11085188/),,6816,6173,DB01536,4-Androstenedione
,11085188,numbers,"Mean GC-R numbers were 5814+/-1574 and 6816+/-1647; mean Kd values were 3.6+/-1.5 nM and 4.2+/-0.7 nM in patient and control groups, respectively.",Glucocorticoid receptors in patients with congenital adrenal hyperplasia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11085188/),,5814,6174,DB01536,4-Androstenedione
,11085188,numbers,"Mean GC-R numbers were 5814+/-1574 and 6816+/-1647; mean Kd values were 3.6+/-1.5 nM and 4.2+/-0.7 nM in patient and control groups, respectively.",Glucocorticoid receptors in patients with congenital adrenal hyperplasia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11085188/),,6816,6175,DB01536,4-Androstenedione
,11085188,Kd,"Mean GC-R numbers were 5814+/-1574 and 6816+/-1647; mean Kd values were 3.6+/-1.5 nM and 4.2+/-0.7 nM in patient and control groups, respectively.",Glucocorticoid receptors in patients with congenital adrenal hyperplasia. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11085188/),nM,3.6,6176,DB01536,4-Androstenedione
,11085188,Kd,"Mean GC-R numbers were 5814+/-1574 and 6816+/-1647; mean Kd values were 3.6+/-1.5 nM and 4.2+/-0.7 nM in patient and control groups, respectively.",Glucocorticoid receptors in patients with congenital adrenal hyperplasia. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11085188/),nM,4.2,6177,DB01536,4-Androstenedione
,25386671,half-life,"Mean (SD) cortisol half-life and Cmax were 1.01 (0.20) hours and 24.4 (5.4) μg/dL, respectively.","Interrelationships among cortisol, 17-hydroxyprogesterone, and androstenendione exposures in the management of children with congenital adrenal hyperplasia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25386671/),h,1.01,15325,DB01536,4-Androstenedione
,25386671,Cmax,"Mean (SD) cortisol half-life and Cmax were 1.01 (0.20) hours and 24.4 (5.4) μg/dL, respectively.","Interrelationships among cortisol, 17-hydroxyprogesterone, and androstenendione exposures in the management of children with congenital adrenal hyperplasia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25386671/),[μg] / [dl],24.4,15326,DB01536,4-Androstenedione
,25386671,AUCs,"The AUCs for cortisol, 17-hydroxyprogesterone and androstenedione were 40.8 (14.5) μg hour/dL, 29,490 (23,539) ng hour/dL, and 680 (795) ng hour/dL, respectively.","Interrelationships among cortisol, 17-hydroxyprogesterone, and androstenendione exposures in the management of children with congenital adrenal hyperplasia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25386671/),[h·μg] / [dl],40.8,15327,DB01536,4-Androstenedione
,25386671,AUCs,"The AUCs for cortisol, 17-hydroxyprogesterone and androstenedione were 40.8 (14.5) μg hour/dL, 29,490 (23,539) ng hour/dL, and 680 (795) ng hour/dL, respectively.","Interrelationships among cortisol, 17-hydroxyprogesterone, and androstenendione exposures in the management of children with congenital adrenal hyperplasia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25386671/),[h·ng] / [dl],"29,490",15328,DB01536,4-Androstenedione
,25386671,AUCs,"The AUCs for cortisol, 17-hydroxyprogesterone and androstenedione were 40.8 (14.5) μg hour/dL, 29,490 (23,539) ng hour/dL, and 680 (795) ng hour/dL, respectively.","Interrelationships among cortisol, 17-hydroxyprogesterone, and androstenendione exposures in the management of children with congenital adrenal hyperplasia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25386671/),[h·ng] / [dl],680,15329,DB01536,4-Androstenedione
,11765025,Peak levels,Peak levels of testosterone total conjugates in urine (range 300-6000 microg/L) were attained a few hours after dosing.,Human nutritional supplements in the horse. Dehydroepiandrosterone versus androstenedione: comparative effects on the androgen profile and consequences for doping analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765025/),[μg] / [l],300-6000,39351,DB01536,4-Androstenedione
,19217534,K(i),"Letrozole (1-[bis-(4-cyanophenyl)methyl]-1H-1,2,4-triazole; Femara) is a high-affinity aromatase inhibitor (K(i)=11.5 nM) that has Food and Drug Administration approval for breast cancer treatment.","Synthesis and PET studies of [(11)C-cyano]letrozole (Femara), an aromatase inhibitor drug. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217534/),nM,11.5,55244,DB01536,4-Androstenedione
,19217534,specific activity,"[(11)C-cyano]Letrozole was synthesized in 60 min with a radiochemical yield of 79-80%, with a radiochemical purity greater than 98% and a specific activity of 4.16+/-2.21 Ci/mumol at the end of bombardment (n=4).","Synthesis and PET studies of [(11)C-cyano]letrozole (Femara), an aromatase inhibitor drug. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217534/),[ci] / [μM],4.16,55245,DB01536,4-Androstenedione
,19217534,free fraction,"The free fraction of letrozole in plasma was 48.9%, and log D was 1.84.","Synthesis and PET studies of [(11)C-cyano]letrozole (Femara), an aromatase inhibitor drug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217534/),%,48.9,55246,DB01536,4-Androstenedione
,19217534,log D,"The free fraction of letrozole in plasma was 48.9%, and log D was 1.84.","Synthesis and PET studies of [(11)C-cyano]letrozole (Femara), an aromatase inhibitor drug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217534/),,1.84,55247,DB01536,4-Androstenedione
,24981575,IC50,"ASP9521 inhibited conversion of AD into T by recombinant human or cynomolgus monkey AKR1C3 in a concentration-dependent manner (IC50,human: 11 nmol/L; IC50,monkey: 49 nmol/L).","In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24981575/),[nM] / [l],11,61031,DB01536,4-Androstenedione
,24981575,IC50,"ASP9521 inhibited conversion of AD into T by recombinant human or cynomolgus monkey AKR1C3 in a concentration-dependent manner (IC50,human: 11 nmol/L; IC50,monkey: 49 nmol/L).","In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24981575/),[nM] / [l],49,61032,DB01536,4-Androstenedione
,24981575,bioavailability,"The bioavailability of ASP9521 after oral administration (1 mg/kg) was 35 %, 78 % and 58 % in rats, dogs and monkeys, respectively.","In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24981575/),%,35,61033,DB01536,4-Androstenedione
,24981575,bioavailability,"The bioavailability of ASP9521 after oral administration (1 mg/kg) was 35 %, 78 % and 58 % in rats, dogs and monkeys, respectively.","In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24981575/),%,78,61034,DB01536,4-Androstenedione
,24981575,bioavailability,"The bioavailability of ASP9521 after oral administration (1 mg/kg) was 35 %, 78 % and 58 % in rats, dogs and monkeys, respectively.","In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24981575/),%,58,61035,DB01536,4-Androstenedione
,4043727,volume of the inner compartment,The volume of the inner compartment was 3.4% for T and E2.,"[Plasma levels, metabolic clearance rates, and rates of secretion of testosterone and estradiol-l7 beta in the silver eel (Anguilla anguilla L.)]. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4043727/),%,3,62198,DB01536,4-Androstenedione
,4043727,biological half-life,The biological half-life was three to four times shorter for T (14.5 hr) than that for E2 (48.5 hr).,"[Plasma levels, metabolic clearance rates, and rates of secretion of testosterone and estradiol-l7 beta in the silver eel (Anguilla anguilla L.)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4043727/),h,14.5,62199,DB01536,4-Androstenedione
,4043727,biological half-life,The biological half-life was three to four times shorter for T (14.5 hr) than that for E2 (48.5 hr).,"[Plasma levels, metabolic clearance rates, and rates of secretion of testosterone and estradiol-l7 beta in the silver eel (Anguilla anguilla L.)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4043727/),h,48.5,62200,DB01536,4-Androstenedione
,4043727,MCR,The MCR for T (1.71 ml/kg body wt/hr) was higher than for E2 (0.51 ml/kg body wt/hr).,"[Plasma levels, metabolic clearance rates, and rates of secretion of testosterone and estradiol-l7 beta in the silver eel (Anguilla anguilla L.)]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4043727/),[ml] / [body·h·kg·wt],1.71,62201,DB01536,4-Androstenedione
,4043727,MCR,The MCR for T (1.71 ml/kg body wt/hr) was higher than for E2 (0.51 ml/kg body wt/hr).,"[Plasma levels, metabolic clearance rates, and rates of secretion of testosterone and estradiol-l7 beta in the silver eel (Anguilla anguilla L.)]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4043727/),[ml] / [body·h·kg·wt],0.51,62202,DB01536,4-Androstenedione
,4043727,protein-bound,"Free or protein-bound hormone levels were 0.12 and 0.31 ng/ml for T and E2, respectively.","[Plasma levels, metabolic clearance rates, and rates of secretion of testosterone and estradiol-l7 beta in the silver eel (Anguilla anguilla L.)]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4043727/),[ng] / [ml],0.12,62203,DB01536,4-Androstenedione
,4043727,protein-bound,"Free or protein-bound hormone levels were 0.12 and 0.31 ng/ml for T and E2, respectively.","[Plasma levels, metabolic clearance rates, and rates of secretion of testosterone and estradiol-l7 beta in the silver eel (Anguilla anguilla L.)]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4043727/),[ng] / [ml],0.31,62204,DB01536,4-Androstenedione
,4043727,production rates,No significant differences were observed between the production rates of T and E2 (0.24 ng/kg body wt/hr).,"[Plasma levels, metabolic clearance rates, and rates of secretion of testosterone and estradiol-l7 beta in the silver eel (Anguilla anguilla L.)]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4043727/),[ng] / [body·h·kg·wt],0.24,62205,DB01536,4-Androstenedione
,11358673,C(max),"Within 24-48 h of the first dose, the circulating drug reached a C(max) of 48.0+/-20.9 nmol/l (mean+/-S.D.; N=7).",Pharmacokinetics and metabolism of formestane in breast cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11358673/),[nM] / [l],48.0,67918,DB01536,4-Androstenedione
,11358673,terminal elimination half-life,"Following i.v. injection of 14C-formestane, the unchanged drug disappeared rapidly from plasma, the terminal elimination half-life being 18+/-2 min (N=3).",Pharmacokinetics and metabolism of formestane in breast cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11358673/),min,18,67919,DB01536,4-Androstenedione
,11358673,"Plasma clearance, CL","Plasma clearance, CL was 4.2+/-1.3 l/(h kg) and the terminal distribution volume V(z) was 1.8+/-0.5 l/kg.",Pharmacokinetics and metabolism of formestane in breast cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11358673/),[l] / [h·kg],4.2,67920,DB01536,4-Androstenedione
,11358673,terminal distribution volume V(z),"Plasma clearance, CL was 4.2+/-1.3 l/(h kg) and the terminal distribution volume V(z) was 1.8+/-0.5 l/kg.",Pharmacokinetics and metabolism of formestane in breast cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11358673/),[l] / [kg],1.8,67921,DB01536,4-Androstenedione
,6374131,metabolic clearance rate,Annual variations of the testosterone metabolic clearance rate (litres/24 h/100 g body wt) were similar to those of testicular androgens; values were high in winter (6.7 +/- 0.7) and lowest in June (3.2 +/- 0.3).,Seasonal changes in testicular contents of testosterone and androstenedione and in the metabolic clearance rate of testosterone in the sand rat (Psammomys obesus). ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374131/),[l] / [100·24·h],6.7,72724,DB01536,4-Androstenedione
,6374131,metabolic clearance rate,Annual variations of the testosterone metabolic clearance rate (litres/24 h/100 g body wt) were similar to those of testicular androgens; values were high in winter (6.7 +/- 0.7) and lowest in June (3.2 +/- 0.3).,Seasonal changes in testicular contents of testosterone and androstenedione and in the metabolic clearance rate of testosterone in the sand rat (Psammomys obesus). ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374131/),[l] / [100·24·h],3.2,72725,DB01536,4-Androstenedione
,124325,metabolic clearance rate,The metabolic clearance rate of progesterone from blood was 3-13 plus or minus 0-35 (S.E.M.) 1/min in ten experiments on six goats; values tended to be slightly higher in pregnant than in non-pregnant goats.,"Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[1] / [min],3-13,86668,DB01536,4-Androstenedione
less,124325,production rate,"The production rate of progesterone at oestrus, and at day 3 of the normal cycle, was less than 0-01 mug/min.","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],0-01,86669,DB01536,4-Androstenedione
,124325,production rate,"During the luteal phase of the oestrous cycle the production rate was 8-5 and 14-6 mug/min in 2 animals, and in the second half of pregnancy, 15-3 plus or minus 0-6 mug/min (5 animals).","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],8-5,86670,DB01536,4-Androstenedione
,124325,production rate,"During the luteal phase of the oestrous cycle the production rate was 8-5 and 14-6 mug/min in 2 animals, and in the second half of pregnancy, 15-3 plus or minus 0-6 mug/min (5 animals).","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],14-6,86671,DB01536,4-Androstenedione
,124325,production rate,"During the luteal phase of the oestrous cycle the production rate was 8-5 and 14-6 mug/min in 2 animals, and in the second half of pregnancy, 15-3 plus or minus 0-6 mug/min (5 animals).","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],15-3,86672,DB01536,4-Androstenedione
,124325,production rate,"During the luteal phase of the oestrous cycle the production rate was 8-5 and 14-6 mug/min in 2 animals, and in the second half of pregnancy, 15-3 plus or minus 0-6 mug/min (5 animals).","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],0-6,86673,DB01536,4-Androstenedione
,124325,clearance rate,"The mean clearance rate of progesterone by the udder was 0-279 1/min, 8-8% of the metabolic clearance rate.","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[1] / [min],0-279,86674,DB01536,4-Androstenedione
,124325,Mammary uptake,"Mammary uptake of progesterone in goats with an actively secreting corpus luteum was 0-64 plus or minus 0-29 mug/min, which gave an estimated value of 0-11-1-88 ng/min/g mammary gland.","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],0-64,86675,DB01536,4-Androstenedione
,124325,Mammary uptake,"Mammary uptake of progesterone in goats with an actively secreting corpus luteum was 0-64 plus or minus 0-29 mug/min, which gave an estimated value of 0-11-1-88 ng/min/g mammary gland.","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[ng] / [g·min],0-11-1-88,86676,DB01536,4-Androstenedione
,9626121,area under the concentration-time curve (AUC) 0-12 h,"Oral administration of 50 mg DHEA led to restoration of DHEA(S) baseline levels, whereas 100 mg induced supraphysiological concentrations [baseline vs. 50 mg DHEA vs. 100 mg DHEA: area under the concentration-time curve (AUC) 0-12 h DHEA: 280 +/- 85 vs.",Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626121/),,280,87582,DB01536,4-Androstenedione
,9626121,AUC 0-12 h,383 +/- 106 nmol/L x h; AUC 0-12 h DHEA(S): 89.1 +/- 48.4 vs. 139.6 +/- 43.5 vs. 213.3 +/- 21.6 mumol/L x h).,Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626121/),[μM] / [h·l],89.1,87583,DB01536,4-Androstenedione
,9626121,AUC 0-12 h,383 +/- 106 nmol/L x h; AUC 0-12 h DHEA(S): 89.1 +/- 48.4 vs. 139.6 +/- 43.5 vs. 213.3 +/- 21.6 mumol/L x h).,Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626121/),[μM] / [h·l],139.6,87584,DB01536,4-Androstenedione
,9626121,AUC 0-12 h,383 +/- 106 nmol/L x h; AUC 0-12 h DHEA(S): 89.1 +/- 48.4 vs. 139.6 +/- 43.5 vs. 213.3 +/- 21.6 mumol/L x h).,Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626121/),[μM] / [h·l],213.3,87585,DB01536,4-Androstenedione
,7315914,metabolic clearance rate of A (MCR-A),"The metabolic clearance rate of A (MCR-A) was increased in pregnant women, 2,825 +/- 207 L/24 hr (mean +/- SEM), compared to 2,020 +/- 140 L/24 hr in nonpregnant women of similar body weight.",Placental clearance rate of maternal plasma androstenedione through placental estradiol formation: an indirect method of assessing uteroplacental blood flow. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7315914/),[l] / [24·h],"2,825",96184,DB01536,4-Androstenedione
,7315914,metabolic clearance rate of A (MCR-A),"The metabolic clearance rate of A (MCR-A) was increased in pregnant women, 2,825 +/- 207 L/24 hr (mean +/- SEM), compared to 2,020 +/- 140 L/24 hr in nonpregnant women of similar body weight.",Placental clearance rate of maternal plasma androstenedione through placental estradiol formation: an indirect method of assessing uteroplacental blood flow. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7315914/),[l] / [24·h],"2,020",96185,DB01536,4-Androstenedione
,7315914,MCR-A,"The immediate puerperal MCR-A was 2,538 +/- 50 L/24 hr.",Placental clearance rate of maternal plasma androstenedione through placental estradiol formation: an indirect method of assessing uteroplacental blood flow. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7315914/),[l] / [24·h],"2,538",96186,DB01536,4-Androstenedione
,7315914,placental clearance rate,"From these data, we computed that the placental clearance rate of A through estradiol (PCAE2) from whole blood was 497 +/- 41 ml/min in women with a single fetus and 691 +/- 102 ml/min in women with twin fetuses.",Placental clearance rate of maternal plasma androstenedione through placental estradiol formation: an indirect method of assessing uteroplacental blood flow. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7315914/),[ml] / [min],497,96187,DB01536,4-Androstenedione
,7315914,placental clearance rate,"From these data, we computed that the placental clearance rate of A through estradiol (PCAE2) from whole blood was 497 +/- 41 ml/min in women with a single fetus and 691 +/- 102 ml/min in women with twin fetuses.",Placental clearance rate of maternal plasma androstenedione through placental estradiol formation: an indirect method of assessing uteroplacental blood flow. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7315914/),[ml] / [min],691,96188,DB01536,4-Androstenedione
,9709932,clearance rate,"The clearance rate of E1S increased from a mean pretreatment value of 5.9 to 14.0 and 10.0 L/h during treatment with DL-AG and D-AG, respectively (P < 0.05, comparing the two on-treatment situations), whereas the production rate of E1S decreased from a pretreatment value of 1.44 to 0.64 nmol/h with DL-AG and 0.36 nmol/h with D-AG (P < 0.05, comparing on-treatment values).","Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9709932/),[l] / [h],5,126038,DB01536,4-Androstenedione
,9709932,clearance rate,"The clearance rate of E1S increased from a mean pretreatment value of 5.9 to 14.0 and 10.0 L/h during treatment with DL-AG and D-AG, respectively (P < 0.05, comparing the two on-treatment situations), whereas the production rate of E1S decreased from a pretreatment value of 1.44 to 0.64 nmol/h with DL-AG and 0.36 nmol/h with D-AG (P < 0.05, comparing on-treatment values).","Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9709932/),[l] / [h],10.0,126039,DB01536,4-Androstenedione
,9709932,production rate,"The clearance rate of E1S increased from a mean pretreatment value of 5.9 to 14.0 and 10.0 L/h during treatment with DL-AG and D-AG, respectively (P < 0.05, comparing the two on-treatment situations), whereas the production rate of E1S decreased from a pretreatment value of 1.44 to 0.64 nmol/h with DL-AG and 0.36 nmol/h with D-AG (P < 0.05, comparing on-treatment values).","Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9709932/),[nM] / [h],1,126040,DB01536,4-Androstenedione
,9709932,production rate,"The clearance rate of E1S increased from a mean pretreatment value of 5.9 to 14.0 and 10.0 L/h during treatment with DL-AG and D-AG, respectively (P < 0.05, comparing the two on-treatment situations), whereas the production rate of E1S decreased from a pretreatment value of 1.44 to 0.64 nmol/h with DL-AG and 0.36 nmol/h with D-AG (P < 0.05, comparing on-treatment values).","Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9709932/),[nM] / [h],0,126041,DB01536,4-Androstenedione
,9709932,production rate,"The clearance rate of E1S increased from a mean pretreatment value of 5.9 to 14.0 and 10.0 L/h during treatment with DL-AG and D-AG, respectively (P < 0.05, comparing the two on-treatment situations), whereas the production rate of E1S decreased from a pretreatment value of 1.44 to 0.64 nmol/h with DL-AG and 0.36 nmol/h with D-AG (P < 0.05, comparing on-treatment values).","Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9709932/),[nM] / [h],0.36,126042,DB01536,4-Androstenedione
,4039394,PCRA,In premenopausal normal women the PCRA is 1950 +/- 184 1/24 h (n = 5) and the PCRT is 484 +/- 82 1/24 h (n = 7).,Deuterium labelled steroid hormones: tracers for the measurement of androgen plasma clearance rates in women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039394/),[1] / [24·h],1950,136270,DB01536,4-Androstenedione
,12970301,metabolic clearance rate,"After a single 10 mg i.v. dose of DHEA, the metabolic clearance rate and terminal half-life of DHEA were 99.9 +/- 9.1 liter/d and 4.5 +/- 0.3 h, respectively.",Bioavailability and pharmacokinetics of dehydroepiandrosterone in the cynomolgus monkey. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12970301/),[l] / [d],99.9,138125,DB01536,4-Androstenedione
,12970301,terminal half-life,"After a single 10 mg i.v. dose of DHEA, the metabolic clearance rate and terminal half-life of DHEA were 99.9 +/- 9.1 liter/d and 4.5 +/- 0.3 h, respectively.",Bioavailability and pharmacokinetics of dehydroepiandrosterone in the cynomolgus monkey. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12970301/),h,4.5,138126,DB01536,4-Androstenedione
,12970301,systemic availability,"Following a 50-mg DHEA PO dose, systemic availability was only 3.1 +/- 0.4%.",Bioavailability and pharmacokinetics of dehydroepiandrosterone in the cynomolgus monkey. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12970301/),%,3.1,138127,DB01536,4-Androstenedione
,12470572,absolute bioavailability,"After intramuscular or subcutaneous administration (absolute bioavailability, 40-50% for both), rHCG pharmacokinetics could be described by a first-order absorption, one-compartment model.",Pharmacokinetics and pharmacodynamics of recombinant human chorionic gonadotrophin in healthy male and female volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12470572/),%,40-50,149396,DB01536,4-Androstenedione
,8789729,metabolic clearance rate,The mean +/- SE metabolic clearance rate of the intravenous DHA was 404 +/- 49 L/day.,Dehydroepiandrosterone metabolism in the female rhesus monkey: oral versus intravenous administration. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789729/),[l] / [d],404,163060,DB01536,4-Androstenedione
,8789729,metabolic clearance rate,"The mean metabolic clearance rate was 2,601 +/- 261 L/day after oral administration, and the calculated absorption was 16.3 +/- 2.5%.",Dehydroepiandrosterone metabolism in the female rhesus monkey: oral versus intravenous administration. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789729/),[l] / [d],"2,601",163061,DB01536,4-Androstenedione
,8789729,absorption,"The mean metabolic clearance rate was 2,601 +/- 261 L/day after oral administration, and the calculated absorption was 16.3 +/- 2.5%.",Dehydroepiandrosterone metabolism in the female rhesus monkey: oral versus intravenous administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789729/),%,16.3,163062,DB01536,4-Androstenedione
,8789729,conversion ratio,"DHA to DHAS, as the conversion ratio of the orally administered DHA measured in the blood as [4-14C]DHAS was 63.3 +/- 13.6, whereas the conversion ratio of intravenously administered DHA to DHAS was 9.3 +/- 2.0.",Dehydroepiandrosterone metabolism in the female rhesus monkey: oral versus intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789729/),,63.3,163063,DB01536,4-Androstenedione
,8789729,conversion ratio,"DHA to DHAS, as the conversion ratio of the orally administered DHA measured in the blood as [4-14C]DHAS was 63.3 +/- 13.6, whereas the conversion ratio of intravenously administered DHA to DHAS was 9.3 +/- 2.0.",Dehydroepiandrosterone metabolism in the female rhesus monkey: oral versus intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789729/),,9.3,163064,DB01536,4-Androstenedione
,2847370,Ki,"MDL 18,962 was shown to be a highly specific, potent (Ki = 3-4 nM), enzyme-activated inhibitor of aromatase with minimal intrinsic endocrine properties.","Biological characterization of 10-(2-propynyl) estr-4-ene-3, 17-dione (MDL 18,962), an enzyme-activated inhibitor of aromatase. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2847370/),nM,3-4,163361,DB01536,4-Androstenedione
,2847370,ED50,"The ED50 for inhibition of aromatase activity in these trophoblast tumors at 6 h post-treatment was 1.4 mg/kg, s.c. and 3.0 mg/kg, oral.","Biological characterization of 10-(2-propynyl) estr-4-ene-3, 17-dione (MDL 18,962), an enzyme-activated inhibitor of aromatase. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2847370/),[mg] / [kg],1.4,163362,DB01536,4-Androstenedione
,2847370,ED50,"The ED50 for inhibition of aromatase activity in these trophoblast tumors at 6 h post-treatment was 1.4 mg/kg, s.c. and 3.0 mg/kg, oral.","Biological characterization of 10-(2-propynyl) estr-4-ene-3, 17-dione (MDL 18,962), an enzyme-activated inhibitor of aromatase. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2847370/),[mg] / [kg],3.0,163363,DB01536,4-Androstenedione
,2847370,ED50,"Preliminary results indicated that the ED50 for inhibition of peripheral aromatization of androgen by MDL 18,962 in female baboons was 0.01 mg/kg, i.v. and 4 mg/kg, oral.","Biological characterization of 10-(2-propynyl) estr-4-ene-3, 17-dione (MDL 18,962), an enzyme-activated inhibitor of aromatase. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2847370/),[mg] / [kg],0.01,163364,DB01536,4-Androstenedione
,2847370,ED50,"Preliminary results indicated that the ED50 for inhibition of peripheral aromatization of androgen by MDL 18,962 in female baboons was 0.01 mg/kg, i.v. and 4 mg/kg, oral.","Biological characterization of 10-(2-propynyl) estr-4-ene-3, 17-dione (MDL 18,962), an enzyme-activated inhibitor of aromatase. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2847370/),[mg] / [kg],4,163365,DB01536,4-Androstenedione
,12782545,AUC,Analysis of integrated area under the curve (AUC) and time 0 hormonal concentrations by repeated measures multivariate analysis of variance (p<0.05) and Fisher's post hoc analysis showed a significant increase in AUC for serum androstenedione at day 0 (108.3 (27.6) nmol/l) in the supplemented condition as compared with day 28 (43.4 (13.1) nmol/l) and placebo (2.1 (0.8) nmol/l) conditions.,Four weeks of androstenedione supplementation diminishes the treatment response in middle aged men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12782545/),[nM] / [l],108.3,177886,DB01536,4-Androstenedione
,12782545,AUC,Analysis of integrated area under the curve (AUC) and time 0 hormonal concentrations by repeated measures multivariate analysis of variance (p<0.05) and Fisher's post hoc analysis showed a significant increase in AUC for serum androstenedione at day 0 (108.3 (27.6) nmol/l) in the supplemented condition as compared with day 28 (43.4 (13.1) nmol/l) and placebo (2.1 (0.8) nmol/l) conditions.,Four weeks of androstenedione supplementation diminishes the treatment response in middle aged men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12782545/),[nM] / [l],43.4,177887,DB01536,4-Androstenedione
,12782545,AUC,Analysis of integrated area under the curve (AUC) and time 0 hormonal concentrations by repeated measures multivariate analysis of variance (p<0.05) and Fisher's post hoc analysis showed a significant increase in AUC for serum androstenedione at day 0 (108.3 (27.6) nmol/l) in the supplemented condition as compared with day 28 (43.4 (13.1) nmol/l) and placebo (2.1 (0.8) nmol/l) conditions.,Four weeks of androstenedione supplementation diminishes the treatment response in middle aged men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12782545/),[nM] / [l],2.1,177888,DB01536,4-Androstenedione
,9394853,clearance half-life,"In all these assays, maximum anastrozole activity was consistently achieved at an oral dose of about 0.1 mg/kg, and the clearance half-life of 7-16 h indicated that once-daily dosing would be possible in humans.",The relevance of preclinical models to the treatment of postmenopausal breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9394853/),h,7-16,185888,DB01536,4-Androstenedione
,9394853,clearance half-life,"The clearance half-life in postmenopausal women is about 50 h, and with once-daily dosing the dose of anastrozole required for maximal inhibition is 1 mg/day.",The relevance of preclinical models to the treatment of postmenopausal breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9394853/),h,50,185889,DB01536,4-Androstenedione
,2917360,half-life,"The half-life of 4-OHA p.o. was approximately 3 h, whereas the apparent half-life of injected drug was between 5 and 10 days after a more rapid clearance during the first 4 days after injection.",Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917360/),h,3,190671,DB01536,4-Androstenedione
,2917360,apparent half-life,"The half-life of 4-OHA p.o. was approximately 3 h, whereas the apparent half-life of injected drug was between 5 and 10 days after a more rapid clearance during the first 4 days after injection.",Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917360/),d,5 and 10,190672,DB01536,4-Androstenedione
,19201664,S/N ratio,"The detection limit of the present GC-MS-SIM method was found to be 1 pg per injection for AD (S/N ratio=4.5), 5 pg for 11beta-OHAD (S/N ratio=5.0), and 1 pg for TS (S/N ratio=4.4), respectively.","Simultaneous determination of androstenedione, 11beta-hydroxyandrostenedione, and testosterone in human plasma by stable isotope dilution mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19201664/),,4.5,196526,DB01536,4-Androstenedione
,19201664,S/N ratio,"The detection limit of the present GC-MS-SIM method was found to be 1 pg per injection for AD (S/N ratio=4.5), 5 pg for 11beta-OHAD (S/N ratio=5.0), and 1 pg for TS (S/N ratio=4.4), respectively.","Simultaneous determination of androstenedione, 11beta-hydroxyandrostenedione, and testosterone in human plasma by stable isotope dilution mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19201664/),pg,5,196527,DB01536,4-Androstenedione
,19201664,S/N ratio,"The detection limit of the present GC-MS-SIM method was found to be 1 pg per injection for AD (S/N ratio=4.5), 5 pg for 11beta-OHAD (S/N ratio=5.0), and 1 pg for TS (S/N ratio=4.4), respectively.","Simultaneous determination of androstenedione, 11beta-hydroxyandrostenedione, and testosterone in human plasma by stable isotope dilution mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19201664/),,5.0,196528,DB01536,4-Androstenedione
,19201664,S/N ratio,"The detection limit of the present GC-MS-SIM method was found to be 1 pg per injection for AD (S/N ratio=4.5), 5 pg for 11beta-OHAD (S/N ratio=5.0), and 1 pg for TS (S/N ratio=4.4), respectively.","Simultaneous determination of androstenedione, 11beta-hydroxyandrostenedione, and testosterone in human plasma by stable isotope dilution mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19201664/),pg,1,196529,DB01536,4-Androstenedione
,19201664,S/N ratio,"The detection limit of the present GC-MS-SIM method was found to be 1 pg per injection for AD (S/N ratio=4.5), 5 pg for 11beta-OHAD (S/N ratio=5.0), and 1 pg for TS (S/N ratio=4.4), respectively.","Simultaneous determination of androstenedione, 11beta-hydroxyandrostenedione, and testosterone in human plasma by stable isotope dilution mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19201664/),,4.4,196530,DB01536,4-Androstenedione
,19567522,bioavailability,"We report a 14.5-year-old boy with CAH who had reduced bioavailability [42% (normal 80% orally and 100% by im route)] and increased clearance [half-life 50 min (normal range, 70-100 min)] of oral doses of hydrocortisone leading to ambient serum 17-hydroxyprogesterone concentrations of 400 nmol/liter (14.5 ng/ml) and androstenedione concentrations of 24.9 nmol/liter (7.1 ng/ml).",Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19567522/),%,42,196903,DB01536,4-Androstenedione
,19567522,bioavailability,"We report a 14.5-year-old boy with CAH who had reduced bioavailability [42% (normal 80% orally and 100% by im route)] and increased clearance [half-life 50 min (normal range, 70-100 min)] of oral doses of hydrocortisone leading to ambient serum 17-hydroxyprogesterone concentrations of 400 nmol/liter (14.5 ng/ml) and androstenedione concentrations of 24.9 nmol/liter (7.1 ng/ml).",Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19567522/),%,80,196904,DB01536,4-Androstenedione
,19567522,bioavailability,"We report a 14.5-year-old boy with CAH who had reduced bioavailability [42% (normal 80% orally and 100% by im route)] and increased clearance [half-life 50 min (normal range, 70-100 min)] of oral doses of hydrocortisone leading to ambient serum 17-hydroxyprogesterone concentrations of 400 nmol/liter (14.5 ng/ml) and androstenedione concentrations of 24.9 nmol/liter (7.1 ng/ml).",Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19567522/),%,100,196905,DB01536,4-Androstenedione
,24434282,IC50,"In an enzymatic assay in homogenized and whole HEK-293 cells overexpressing 17β-HSD3, the inhibitor RM-532-105 efficiently inhibited the conversion of natural substrate 4-dione (50nM) into T with an IC50 of 26nM and 5nM, respectively.",In vitro and in vivo evaluation of a 3β-androsterone derivative as inhibitor of 17β-hydroxysteroid dehydrogenase type 3. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24434282/),nM,26,197900,DB01536,4-Androstenedione
,24434282,IC50,"In an enzymatic assay in homogenized and whole HEK-293 cells overexpressing 17β-HSD3, the inhibitor RM-532-105 efficiently inhibited the conversion of natural substrate 4-dione (50nM) into T with an IC50 of 26nM and 5nM, respectively.",In vitro and in vivo evaluation of a 3β-androsterone derivative as inhibitor of 17β-hydroxysteroid dehydrogenase type 3. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24434282/),nM,5,197901,DB01536,4-Androstenedione
,24434282,AUC 24h,"Moreover, the inhibitor RM-532-105 (10mg/kg) reached a plasma concentration of 250ng/mL at 7h (AUC 24h: 3485ngh/mL) after subcutaneous (s.c.) injection in the rat.",In vitro and in vivo evaluation of a 3β-androsterone derivative as inhibitor of 17β-hydroxysteroid dehydrogenase type 3. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24434282/),[ngh] / [ml],3485,197902,DB01536,4-Androstenedione
,5103749,metabolic clearance rate,"The mean dihydrotestosterone metabolic clearance rate was higher in men (336 liters/24 hr per m(2) [range, 239-448]) than in women (153 liters/24 hr per m(2) [range, 108-184]).",The metabolic clearance rate and origin of plasma dihydrotestosterone in man and its conversion to the 5-alpha-androstanediols. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5103749/),[24·h·l] / [m(2],336,200510,DB01536,4-Androstenedione
,5103749,metabolic clearance rate,"The mean dihydrotestosterone metabolic clearance rate was higher in men (336 liters/24 hr per m(2) [range, 239-448]) than in women (153 liters/24 hr per m(2) [range, 108-184]).",The metabolic clearance rate and origin of plasma dihydrotestosterone in man and its conversion to the 5-alpha-androstanediols. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5103749/),[24·h·l] / [m(2],153,200511,DB01536,4-Androstenedione
,2123133,time to peak,The median time to peak was 1.5 h for both preparations and the elimination rate constants were similar (0.31 for micronized 4-OHA and 0.36 h-1 for formulated 4-OHA).,Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2123133/),h,1.5,203603,DB01536,4-Androstenedione
,2123133,elimination rate constants,The median time to peak was 1.5 h for both preparations and the elimination rate constants were similar (0.31 for micronized 4-OHA and 0.36 h-1 for formulated 4-OHA).,Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2123133/),1/[h],0.31,203604,DB01536,4-Androstenedione
,2123133,elimination rate constants,The median time to peak was 1.5 h for both preparations and the elimination rate constants were similar (0.31 for micronized 4-OHA and 0.36 h-1 for formulated 4-OHA).,Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2123133/),1/[h],0.36,203605,DB01536,4-Androstenedione
,1394219,Peak plasma exemestane concentrations,"Peak plasma exemestane concentrations of 27, 221, 343, and 414 ng/ml were reached within 2 h after administration of 50, 200, 400, and 800 mg, respectively.","Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394219/),[ng] / [ml],27,207812,DB01536,4-Androstenedione
,1394219,Peak plasma exemestane concentrations,"Peak plasma exemestane concentrations of 27, 221, 343, and 414 ng/ml were reached within 2 h after administration of 50, 200, 400, and 800 mg, respectively.","Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394219/),[ng] / [ml],221,207813,DB01536,4-Androstenedione
,1394219,Peak plasma exemestane concentrations,"Peak plasma exemestane concentrations of 27, 221, 343, and 414 ng/ml were reached within 2 h after administration of 50, 200, 400, and 800 mg, respectively.","Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394219/),[ng] / [ml],343,207814,DB01536,4-Androstenedione
,1394219,Peak plasma exemestane concentrations,"Peak plasma exemestane concentrations of 27, 221, 343, and 414 ng/ml were reached within 2 h after administration of 50, 200, 400, and 800 mg, respectively.","Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394219/),[ng] / [ml],414,207815,DB01536,4-Androstenedione
,16525862,half-life of,"The half-life of the induction process was estimated to be 2 days for CYP1A2, CYP3A1/2, and CYP2B1/2, and 3 days for androstenedione producing enzymes.",A mechanism-based integrated pharmacokinetic enzyme model describing the time course and magnitude of phenobarbital-mediated enzyme induction in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16525862/),d,2,218374,DB01536,4-Androstenedione
,16525862,half-life of,"The half-life of the induction process was estimated to be 2 days for CYP1A2, CYP3A1/2, and CYP2B1/2, and 3 days for androstenedione producing enzymes.",A mechanism-based integrated pharmacokinetic enzyme model describing the time course and magnitude of phenobarbital-mediated enzyme induction in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16525862/),d,3,218375,DB01536,4-Androstenedione
,5020435,MCR(,"In eight normal men, the MCR(T) (516+/-108 [SD] liters/m(2)/day) was significantly greater than the MCR(DHT) (391+/-71 [SD] liters/m(2)/day).","Metabolic clearance rate and blood production rate of testosterone and dihydrotestosterone in normal subjects, during pregnancy, and in hyperthyroidism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5020435/),[l] / [d·m(2)],516,219256,DB01536,4-Androstenedione
,5020435,MCR,"In eight normal men, the MCR(T) (516+/-108 [SD] liters/m(2)/day) was significantly greater than the MCR(DHT) (391+/-71 [SD] liters/m(2)/day).","Metabolic clearance rate and blood production rate of testosterone and dihydrotestosterone in normal subjects, during pregnancy, and in hyperthyroidism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5020435/),[l] / [d·m(2)],391,219257,DB01536,4-Androstenedione
,5020435,MCR(T),"In seven females, the MCR(T) (304+/-53 [SD] liters/m(2)/day) was also greater than the MCR(DHT) (209+/-45 [SD] liters/m(2)/day) and both values were less than their respective values in men (P < 0.001).","Metabolic clearance rate and blood production rate of testosterone and dihydrotestosterone in normal subjects, during pregnancy, and in hyperthyroidism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5020435/),[l] / [d·m(2)],304,219258,DB01536,4-Androstenedione
,5020435,MCR(,"In seven females, the MCR(T) (304+/-53 [SD] liters/m(2)/day) was also greater than the MCR(DHT) (209+/-45 [SD] liters/m(2)/day) and both values were less than their respective values in men (P < 0.001).","Metabolic clearance rate and blood production rate of testosterone and dihydrotestosterone in normal subjects, during pregnancy, and in hyperthyroidism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5020435/),[l] / [d·m(2)],209,219259,DB01536,4-Androstenedione
,5020435,MCR(T),"In five pregnant females the MCR(T) (192+/-36 [SD] liters/m(2)/day), the MCR(DHT) (89+/-30 [SD] liters/m(2)/day) and the conversion of testosterone into dihydrotestosterone (0.72+/-0.15%) (SD) were significantly less than the values found in nonpregnant women.","Metabolic clearance rate and blood production rate of testosterone and dihydrotestosterone in normal subjects, during pregnancy, and in hyperthyroidism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5020435/),[l] / [d·m(2)],192,219260,DB01536,4-Androstenedione
,5020435,MCR(DHT),"In five pregnant females the MCR(T) (192+/-36 [SD] liters/m(2)/day), the MCR(DHT) (89+/-30 [SD] liters/m(2)/day) and the conversion of testosterone into dihydrotestosterone (0.72+/-0.15%) (SD) were significantly less than the values found in nonpregnant women.","Metabolic clearance rate and blood production rate of testosterone and dihydrotestosterone in normal subjects, during pregnancy, and in hyperthyroidism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5020435/),[l] / [d·m(2)],89,219261,DB01536,4-Androstenedione
,5020435,production,"In men the production of dihydrotestosterone was 0.39+/-0.1 (SD) mg/day, 50% being derived from the transformation of plasma testosterone.","Metabolic clearance rate and blood production rate of testosterone and dihydrotestosterone in normal subjects, during pregnancy, and in hyperthyroidism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5020435/),[mg] / [d],0.39,219262,DB01536,4-Androstenedione
,5020435,production,"In women the production of DHT was 0.05+/-0.028 (SD) mg/day, only 10% coming from testosterone.","Metabolic clearance rate and blood production rate of testosterone and dihydrotestosterone in normal subjects, during pregnancy, and in hyperthyroidism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5020435/),[mg] / [d],0.05,219263,DB01536,4-Androstenedione
,2146284,"drug inhibitory constant, KI","The drug inhibitory constant, KI, for the estrone synthetic pathway, was 3.0 ng/mL (13.4 nmol/L) and was of similar magnitude as that determined under in vitro conditions.","The pharmacodynamic inhibition of estrogen synthesis by fadrozole, an aromatase inhibitor, and its pharmacokinetic disposition. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146284/),[ng] / [ml],3.0,222325,DB01536,4-Androstenedione
,2146284,"drug inhibitory constant, KI","The drug inhibitory constant, KI, for the estrone synthetic pathway, was 3.0 ng/mL (13.4 nmol/L) and was of similar magnitude as that determined under in vitro conditions.","The pharmacodynamic inhibition of estrogen synthesis by fadrozole, an aromatase inhibitor, and its pharmacokinetic disposition. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146284/),[nM] / [l],13.4,222326,DB01536,4-Androstenedione
,2146284,KI,The KI for the estradiol synthetic pathway was 5.3 ng/mL (23.7 nmol/L).,"The pharmacodynamic inhibition of estrogen synthesis by fadrozole, an aromatase inhibitor, and its pharmacokinetic disposition. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146284/),[ng] / [ml],5.3,222327,DB01536,4-Androstenedione
,2146284,KI,The KI for the estradiol synthetic pathway was 5.3 ng/mL (23.7 nmol/L).,"The pharmacodynamic inhibition of estrogen synthesis by fadrozole, an aromatase inhibitor, and its pharmacokinetic disposition. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146284/),[nM] / [l],23.7,222328,DB01536,4-Androstenedione
,2146284,half-life,"The average half-life and oral clearance values were 10.5 h and 621 mL/min, respectively.","The pharmacodynamic inhibition of estrogen synthesis by fadrozole, an aromatase inhibitor, and its pharmacokinetic disposition. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146284/),h,10.5,222329,DB01536,4-Androstenedione
,2146284,oral clearance,"The average half-life and oral clearance values were 10.5 h and 621 mL/min, respectively.","The pharmacodynamic inhibition of estrogen synthesis by fadrozole, an aromatase inhibitor, and its pharmacokinetic disposition. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146284/),[ml] / [min],621,222330,DB01536,4-Androstenedione
,10372727,area under the curve (AUC) 0-12 h,"The intake of 50 mg DHEA led to an increase in serum DHEAS to mean levels of young adult men, whereas 100 mg DHEA induced supraphysiological concentrations [placebo vs. 50 mg DHEA vs. 100 mg DHEA; area under the curve (AUC) 0-12 h (mean +/- SD) for DHEA, 108 +/- 22 vs.",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),,108,228141,DB01536,4-Androstenedione
,10372727,AUC 0-12 h,"349 +/- 72 nmol/L x h; AUC 0-12 h for DHEAS, 33 +/- 9 vs. 114 +/- 19 vs. 164 +/- 36 micromol/L x h].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[μM] / [h·l],33,228142,DB01536,4-Androstenedione
,10372727,AUC 0-12 h,"349 +/- 72 nmol/L x h; AUC 0-12 h for DHEAS, 33 +/- 9 vs. 114 +/- 19 vs. 164 +/- 36 micromol/L x h].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[μM] / [h·l],114,228143,DB01536,4-Androstenedione
,10372727,AUC 0-12 h,"349 +/- 72 nmol/L x h; AUC 0-12 h for DHEAS, 33 +/- 9 vs. 114 +/- 19 vs. 164 +/- 36 micromol/L x h].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[μM] / [h·l],164,228144,DB01536,4-Androstenedione
,10372727,AUC 0-12 h,"In contrast, 17beta-estradiol and estrone significantly increased in a dose-dependent manner to concentrations still within the upper normal range for men [placebo vs. 50 mg DHEA vs. 100 mg DHEA; AUC 0-12 h for 17beta-estradiol, 510 +/- 198 vs. 635 +/- 156 vs.",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),,510,228145,DB01536,4-Androstenedione
,10372727,AUC 0-12 h,"In contrast, 17beta-estradiol and estrone significantly increased in a dose-dependent manner to concentrations still within the upper normal range for men [placebo vs. 50 mg DHEA vs. 100 mg DHEA; AUC 0-12 h for 17beta-estradiol, 510 +/- 198 vs. 635 +/- 156 vs.",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),,635,228146,DB01536,4-Androstenedione
,10372727,AUC 0-12 h,"700 +/- 209 pmol/L x h (P < 0.0001); AUC 0-12 h for estrone, 1443 +/- 269 vs. 2537 +/- 434 vs. 3254 +/- 671 pmol/L x h (P < 0.0001)].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[pM] / [h·l],1443,228147,DB01536,4-Androstenedione
,10372727,AUC 0-12 h,"700 +/- 209 pmol/L x h (P < 0.0001); AUC 0-12 h for estrone, 1443 +/- 269 vs. 2537 +/- 434 vs. 3254 +/- 671 pmol/L x h (P < 0.0001)].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[pM] / [h·l],2537,228148,DB01536,4-Androstenedione
,10372727,AUC 0-12 h,"700 +/- 209 pmol/L x h (P < 0.0001); AUC 0-12 h for estrone, 1443 +/- 269 vs. 2537 +/- 434 vs. 3254 +/- 671 pmol/L x h (P < 0.0001)].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[pM] / [h·l],3254,228149,DB01536,4-Androstenedione
,24771350,half-life (t1/2),"PK demonstrated a half-life (t1/2) ranging from 16 to 35 h, rapid absorption and dose proportionality.","Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24771350/),h,16 to 35,237567,DB01536,4-Androstenedione
,32652643,apparent clearance,"Cortisol was characterized by a one-compartment model with apparent clearance and volume of distribution estimated at 22.9 L/h/70 kg and 41.1 L/70 kg, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),[l] / [70·h·kg],22.9,240366,DB01536,4-Androstenedione
,32652643,volume of distribution,"Cortisol was characterized by a one-compartment model with apparent clearance and volume of distribution estimated at 22.9 L/h/70 kg and 41.1 L/70 kg, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),[l] / [70·kg],41.1,240367,DB01536,4-Androstenedione
,32652643,IC50,"The IC50 values of cortisol concentrations for cortisol, 17-hydroxyprogesterone and androstenedione were estimated to be 1.36, 0.45 and 0.75 μg/dL, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),[μg] / [dl],1.36,240368,DB01536,4-Androstenedione
,32652643,IC50,"The IC50 values of cortisol concentrations for cortisol, 17-hydroxyprogesterone and androstenedione were estimated to be 1.36, 0.45 and 0.75 μg/dL, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),[μg] / [dl],0.45,240369,DB01536,4-Androstenedione
,32652643,IC50,"The IC50 values of cortisol concentrations for cortisol, 17-hydroxyprogesterone and androstenedione were estimated to be 1.36, 0.45 and 0.75 μg/dL, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),[μg] / [dl],0.75,240370,DB01536,4-Androstenedione
,32652643,Half-lives,"Half-lives of cortisol, 17-hydroxyprogesterone and androstenedione were 60, 47 and 77 minutes, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),min,60,240371,DB01536,4-Androstenedione
,32652643,Half-lives,"Half-lives of cortisol, 17-hydroxyprogesterone and androstenedione were 60, 47 and 77 minutes, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),min,47,240372,DB01536,4-Androstenedione
,32652643,Half-lives,"Half-lives of cortisol, 17-hydroxyprogesterone and androstenedione were 60, 47 and 77 minutes, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),min,77,240373,DB01536,4-Androstenedione
,8943796,metabolic clearance rate (MCR),"DHEA is cleared rapidly from the blood, with a metabolic clearance rate (MCR) in the range of 2000 I/day, but the clearance of DHEAS is much slower and its MCR is in the range of 131/day.",Dehydroepiandrosterone metabolism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8943796/),[i] / [d],2000,245145,DB01536,4-Androstenedione
,8943796,MCR,"DHEA is cleared rapidly from the blood, with a metabolic clearance rate (MCR) in the range of 2000 I/day, but the clearance of DHEAS is much slower and its MCR is in the range of 131/day.",Dehydroepiandrosterone metabolism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8943796/),1/[d],131,245146,DB01536,4-Androstenedione
,9296217,overall response rates,"The overall response rates were 30% and 40% on 250 mg and 500 mg, respectively.","A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296217/),%,30,266486,DB01536,4-Androstenedione
,9296217,overall response rates,"The overall response rates were 30% and 40% on 250 mg and 500 mg, respectively.","A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296217/),%,40,266487,DB01536,4-Androstenedione
,11438316,maximum testosterone levels,Mean maximum testosterone levels obtained with the lozenge occurred 1 hour after administration on days 1 (692 +/- 236 ng/dL) and 14 (836 +/- 309 ng/dL) of treatment and fell precipitously thereafter.,Pharmacokinetics of testosterone after percutaneous gel or buccal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11438316/),[ng] / [dl],692,269515,DB01536,4-Androstenedione
,11438316,maximum testosterone levels,Mean maximum testosterone levels obtained with the lozenge occurred 1 hour after administration on days 1 (692 +/- 236 ng/dL) and 14 (836 +/- 309 ng/dL) of treatment and fell precipitously thereafter.,Pharmacokinetics of testosterone after percutaneous gel or buccal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11438316/),[ng] / [dl],836,269516,DB01536,4-Androstenedione
,11438316,maximal levels,"In contrast, testosterone levels obtained with the gel showed a prolonged rise reaching maximal levels of 97 +/- 78 and 100 +/- 60 ng/dL after 18 hours.",Pharmacokinetics of testosterone after percutaneous gel or buccal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11438316/),[ng] / [dl],97,269517,DB01536,4-Androstenedione
,11438316,maximal levels,"In contrast, testosterone levels obtained with the gel showed a prolonged rise reaching maximal levels of 97 +/- 78 and 100 +/- 60 ng/dL after 18 hours.",Pharmacokinetics of testosterone after percutaneous gel or buccal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11438316/),[ng] / [dl],100,269518,DB01536,4-Androstenedione
